NASDAQ · Biotechnology

MTVA (MTVA) Stock

$1.42 -1.39% NASDAQ: MTVA Healthcare

Valuation

MetricValue
Price$1.42
Market Cap$3.13M
P/E Ratio-0.16
P/B Ratio0.52
P/S Ratio0.00
EPS (TTM)$-7.35
52-Week High$19.03
52-Week Low$0.97
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-260.00%
ROA-18.84%
ROCE-280.00%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.02
Current Ratio1.83

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-15.0M$-20.0M$-16.0M$-29.0M$-14.0M
Net Profit$-15.0M$-14.0M$-12.0M$-28.0M$-13.0M
EPS$-1742.40$-477.84$-27.06$-39.16$-7.35
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$17.0M$34.0M$23.0M$16.0M$69.0M
Total Liabilities$2.0M$12.0M$6.0M$8.0M$64.0M
Cash$16.0M$33.0M$22.0M$16.0M$10.0M
Borrowings$0$0$0$0$0

Latest News

Sector Update: Healthcare Stocks Softer Late Afternoon MT Newswires · Jul 9, 2026 Sector Update: Healthcare Stocks Decline in Afternoon Trading MT Newswires · Jul 9, 2026 MetaVia Says Patients on Experimental Obesity Drug Reach Highest Target Doses in Phase 1 Trial MT Newswires · Jul 9, 2026 MetaVia Announces Completion of Dose Titration in Phase 1 Part 3 Study of DA-1726 for the Treatment of Obesity PR Newswire · Jul 9, 2026 OTC Markets Life Sciences Investor Forum: MetaVia CEO HH Kim and CFO Marshall Woodworth with Zacks SCR's David Bautz Zacks Small Cap Research · Jun 30, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-15.0M$-12.0M$-11.0M$-25.0M$-16.0M
Investing Cash Flow$-1.0M$0$0$0$0
Financing Cash Flow$-2.0M$-36.0M$0$-2.0M$0
Net Cash Flow$6.0M$17.0M$-11.0M$-6.0M$-6.0M
Free Cash Flow$-15.0M$-12.0M$-11.0M$-25.0M$-16.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-619.82%
Quick Ratio2.73
Interest Coverage—
Return 1Y-74.82%
Return 3Y-95.19%
Return 5Y-99.97%

Ownership

Insiders Held36.50%
Institutions Held13.38%
Institutions Float Held21.07%
Institutional HolderSharesReport Date
Geode Capital Management, LLC33,6352026-03-31
Jane Street Group, LLC10,9032026-03-31
Aries Wealth Management10,0002026-03-31
Vanguard Fiduciary Trust Co6,9402026-03-31
Tower Research Capital LLC (TRC)2,6022026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
CASICASI Pharmaceuticals, Inc. $0.15 +3.08% -0.07 $2.33M 0.00%
CLGN $0.27 -9.04% -0.48 $3.54M 0.00%
CLSDClearside Biomedical, Inc. $0.41 +0.00% -0.11 $2.15M 0.00%
ENLV $2.12 -5.36% 0.03 $35.68M 0.00%
KLTOKlotho Neurosciences, Inc. $0.38 -7.10% -1.13 $20.08M 0.00%

About MTVA

MTVA is led by CEO Hyung Heon Kim, employs 9 people, headquartered in US, publicly traded since 2016.

MTVA stock trades at $1.42 with a market capitalization of $3.13M. The stock is valued at a price-to-earnings (P/E) ratio of -0.16, price-to-book of 0.52, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.97 and $19.03, and currently trades 92.5% below its 52-week high.

On profitability, MTVA generates a return on equity (ROE) of -260.00%, return on capital employed of -280.00%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides